This study is testing whether combining two targeted drugs—sacituzumab govitecan and trastuzumab—can help control metastatic HER2-positive breast cancer that has progressed after standard treatments. The trial will enroll about 28 patients who have already received specific prior…
Phase: PHASE2 • Sponsor: Adrienne G. Waks • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC